Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IDARUCIZUMAB Cause Hepatic function abnormal? 6 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Hepatic function abnormal have been filed in association with IDARUCIZUMAB (Praxbind). This represents 0.4% of all adverse event reports for IDARUCIZUMAB.

6
Reports of Hepatic function abnormal with IDARUCIZUMAB
0.4%
of all IDARUCIZUMAB reports
1
Deaths
4
Hospitalizations

How Dangerous Is Hepatic function abnormal From IDARUCIZUMAB?

Of the 6 reports, 1 (16.7%) resulted in death, 4 (66.7%) required hospitalization, and 2 (33.3%) were considered life-threatening.

Is Hepatic function abnormal Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IDARUCIZUMAB. However, 6 reports have been filed with the FAERS database.

What Other Side Effects Does IDARUCIZUMAB Cause?

Death (170) Haemorrhage (110) Cerebral haemorrhage (92) Gastrointestinal haemorrhage (83) Haemorrhage intracranial (68) Multiple organ dysfunction syndrome (68) Drug ineffective (58) Pneumonia (51) Acute kidney injury (49) Cerebral infarction (46)

What Other Drugs Cause Hepatic function abnormal?

NIVOLUMAB (1,131) PEMBROLIZUMAB (1,079) METHOTREXATE (1,054) CABOZANTINIB S-MALATE (912) CYCLOPHOSPHAMIDE (824) BEVACIZUMAB (769) PACLITAXEL (603) LENVATINIB (528) ATORVASTATIN (520) CYCLOSPORINE (508)

Which IDARUCIZUMAB Alternatives Have Lower Hepatic function abnormal Risk?

IDARUCIZUMAB vs IDECABTAGENE VICLEUCEL IDARUCIZUMAB vs IDELALISIB IDARUCIZUMAB vs IDURSULFASE IDARUCIZUMAB vs IFOSFAMIDE IDARUCIZUMAB vs IGURATIMOD

Related Pages

IDARUCIZUMAB Full Profile All Hepatic function abnormal Reports All Drugs Causing Hepatic function abnormal IDARUCIZUMAB Demographics